Author

J. W. Wotring

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cell Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Assay:imaging· 2 Organism:C. elegans· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

J. Z. Sexton· 5 shared M. J. O'Meara· 4 shared C. E. Wobus· 3 shared C. Mirabelli· 3 shared C. J. Zhang· 2 shared R. Fursmidt· 2 shared S. M. McCarty· 2 shared T. R. O'Meara· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

J. Z. Sexton

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Imaging-based screening identifies modulators of the eIF3 translation initiation factor complex in Candida albicans

K. Metzner, M. J. O'Meara, B. Halligan, J. W. Wotring, J. Z. Sexton, T. R. O'Meara

The paper uses imaging-based screening to identify compounds that inhibit hyphal transition in C. albicans, identifying eIF3 as a target of NSC 697923.

bioRxiv · Apr 19, 2023 · PreprintMicrobiology

High-Content Screening to Identify Inhibitors of Dengue Virus Replication

J. G. Hoffstadt, J. W. Wotring, S. Porter, B. S. Halligan, M. J. O'Meara, A. W. Tai, J. Z. Sexton

This study identifies four nanomolar inhibitors of Dengue Virus replication using high-content screening and a viral pseudotime model.

bioRxiv · Mar 24, 2023 · PreprintCell Biology

In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.

J. W. Wotring, S. M. McCarty, K. Shafiq, C. J. Zhang, T. Nguyen, S. R. Meyer, R. Fursmidt, C. Mirabelli, M. C. Clasby, C. E. Wobus, M. J. O'Meara, J. Z. Sexton

This study evaluates niclosamide's limitations as a COVID-19 treatment and identifies analogs with improved potency and reduced toxicity.

bioRxiv · Jun 24, 2022Microbiology

ARF6 is a host factor for SARS-CoV-2 infection in vitro

C. Mirabelli, E. J. Sherman, J. Bragazzi Cunha, J. W. Wotring, J. El Saghir, J. Harder, J. Z. Sexton, B. T. Emmer, C. E. Wobus

This study identifies ARF6 as a host factor critical for SARS-CoV-2 entry and infection in vitro, showing its importance across different cell models.

bioRxiv · Jun 9, 2022 · PreprintMicrobiology

Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19

C. Mirabelli, J. W. Wotring, C. J. Zhang, S. M. McCarty, R. Fursmidt, T. Frum, N. S. Kadambi, A. T. Amin, T. R. O'Meara, C. D. Pretto-Kernahan, J. R. Spence, J. Huang, K. D. Alysandratos, D. N. Kotton, S. K. Handelman, , J. Z. Sexton

This study identifies 17 FDA-approved compounds with antiviral efficacy against SARS-CoV-2 using high-throughput screening and finds lactoferrin as a promising drug candidate with multiple antiviral mechanisms.

Proceedings of the National Academy of Sciences · Aug 19, 2021Peer-reviewedCell Biology